Home Cart Sign in  
Chemical Structure| 910487-58-0 Chemical Structure| 910487-58-0

Structure of BAY 60-6583
CAS No.: 910487-58-0

Chemical Structure| 910487-58-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BAY 60-6583 is a potent adenosine A2B receptor agonist with EC50 of 2.83 nM for murine A2B receptor.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BAY 60-6583

CAS No. :910487-58-0
Formula : C19H17N5O2S
M.W : 379.44
SMILES Code : NC1=NC(SCC(N)=O)=C(C#N)C(C2=CC=C(OCC3CC3)C=C2)=C1C#N
MDL No. :MFCD22683833
InChI Key :ZTYHZMAZUWOXNC-UHFFFAOYSA-N
Pubchem ID :11717831

Safety of BAY 60-6583

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H312-H332
Precautionary Statements:P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P330-P363-P501

Related Pathways of BAY 60-6583

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Enteric Glial Cells (EGCs) 0.05 μM 18 h BAY60-6583 reduced TLR4 expression as well as IL-1β, GDNF, and SP release. Cells. 2020 May 18;9(5):1245
CHO cells 10 μM 10 min To test the agonistic effect of BAY 60-6583 on A3 receptors. Results showed BAY 60-6583 had no agonistic effect on A3 receptors at 10 μM concentration. J Mol Cell Cardiol. 2007 Sep;43(3):262-71
CHO cells 3–10 nM 4 h To determine the selective activation of BAY 60-6583 on A2b receptors. Results showed BAY 60-6583 has high selectivity for A2b receptors. J Mol Cell Cardiol. 2007 Sep;43(3):262-71
T84 intestinal epithelial cells 10 μM 60 min To assess the role of Adora2b signaling in barrier recovery in a calcium switch model, results showed that Adora2b agonist treatment significantly enhanced the rate of barrier recovery, accompanied by rapid and sustained elevation of VASP (Ser157) phosphorylation Mucosal Immunol. 2015 Nov;8(6):1324-38
Caco-2 intestinal epithelial cells 10 μM 6 h To evaluate the effect of Adora2b agonist on NF-κB transcriptional activity, results showed that co-treatment with TNF-α or IL-1β did not affect NF-κB transcriptional activity Mucosal Immunol. 2015 Nov;8(6):1324-38
T84 intestinal epithelial cells 10 μM 30 min To assess the effect of Adora2b agonist on MLC phosphorylation status, results showed that treatment for 30 min or 180 min did not alter MLC phosphorylation Mucosal Immunol. 2015 Nov;8(6):1324-38
T84 intestinal epithelial cells 10 μM 72 h To evaluate the effect of Adora2b agonist on cytokine-induced epithelial barrier permeability, results showed that Adora2b agonist treatment did not suppress the cytokine-induced increase in barrier permeability Mucosal Immunol. 2015 Nov;8(6):1324-38
Rabbit cardiomyocytes 1 μM 10 min BAY 60-6583 inhibited rotenone-induced superoxide production from mitochondrial complex I via A2B adenosine receptors, an effect blocked by PD 98059, wortmannin, or PTX. Br J Pharmacol. 2011 Jul;163(5):995-1006
HEK-A2B cells 1 μM 5 min BAY 60-6583 increased ERK phosphorylation via A2B adenosine receptor activation, independent of cAMP or PKA, but inhibited by Pertussis toxin (PTX), indicating receptor coupling to Gi/o proteins. Br J Pharmacol. 2011 Jul;163(5):995-1006
B16-F10 melanoma cells 1 μM 20 h To evaluate the effect of BAY 60-6583 on MDSC functionality, results showed that BAY 60-6583 did not affect the ability of MDSCs to suppress T cell proliferation or IL-10 production. Neoplasia. 2013 Dec;15(12):1400-9

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rats Age-related ED (AED), bilateral cavernous nerve crush (BCNC), and diabetes mellitus-induced ED (DMED) models Caudal vein injection 60 μg/kg Once daily for 28 days Evaluate the therapeutic effects of BAY 60-6583 in three refractory ED models. Results showed that BAY 60-6583 significantly improved erectile function and down-regulated HIF-1α and TGF-β expression. Adv Sci (Weinh). 2024 Aug;11(30):e2306514.
Rats Transient middle cerebral artery occlusion model Intravenous injection 1 mg/kg Single dose at the start of reperfusion BAY 60-6583 administered at the start of reperfusion reduced lesion volume with or without tPA (10 mg/kg), attenuated brain swelling, blood-brain barrier disruption, and tPA-exacerbated HT at 24 h, and mitigated sensorimotor deficits in the presence of tPA. Neurobiol Dis. 2017 Dec;108:173-182
New Zealand White rabbits Regional ischemia/reperfusion model Perfusion 300 nM 60 minutes To evaluate the protective effect of BAY 60-6583 on myocardial infarction during reperfusion. Results showed BAY 60-6583 significantly reduced infarct size. J Mol Cell Cardiol. 2007 Sep;43(3):262-71
Mice Renal ischemia model Intravenous injection 60 μg/kg Single dose BAY 60-6583 treatment dramatically improved renal function and histology following ischemia alone, and this protection was not observed in A2BAR knockout mice. PLoS Med. 2008 Jun 24;5(6):e137
C57Bl6j mice B16-F10 melanoma model Peritumoral injection 0.2 mg/kg Four consecutive days To investigate the effect of BAY 60-6583 on melanoma growth, results showed that BAY 60-6583 significantly promoted melanoma growth, increased the number of MDSCs in tumor tissues, and elevated levels of immune-suppressive mediators IL-10 and MCP-1. Neoplasia. 2013 Dec;15(12):1400-9
Rats Infarction model Intravenous injection 1.0 mg/kg Single dose, observed for 2 hours BAY 60-6583 reduced infarct size in the infarction model J Mol Cell Cardiol. 2010 Nov;49(5):886-93

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.64mL

0.53mL

0.26mL

13.18mL

2.64mL

1.32mL

26.35mL

5.27mL

2.64mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories